








Postoperative CEA is a better
prognostic marker than CA19-9, hCGb
or TATI after resection of colorectal
liver metastases
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Abstract
Liver metastases of colorectal cancer can be operated with a curative intent in selected cases. However, more than half
of the patients have a recurrence. The aim of this study was to evaluate the prognostic and predictive value of
carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), human chorionic gonadotropin b (hCGb) and
tumour-associated trypsin-inhibitor (TATI) in colorectal cancer patients before and 3 months after resection of liver
metastases. Marker concentrations were determined in blood samples from 168 colorectal cancer patients, who
underwent liver resection between the years 1998 and 2007 at Helsinki University Hospital, Finland. The samples were
taken before and 3 months after curative resection. Increased concentrations of CEA (.5 mg/L) and hCGb (.1 pmol/L)
3 months after liver resection correlated with recurrence and impaired overall survival and increased CA19-9 (.26 kU/
L) with impaired overall survival, but postoperative TATI was not prognostic. Preoperatively elevated CEA and CA19-9
correlated with impaired overall survival, but not with recurrence. Neither preoperative hCGb nor TATI was
prognostic. In conclusion, CEA is a useful prognostic marker, when measured 3 months after resection of colorectal liver
metastases. CA19-9 also has prognostic significance and may have additional value.
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Introduction
Colorectal cancer (CRC) is the third most common
cancer worldwide and the second leading cause of can-
cer death in Western countries.1 About half of CRC
patients develop either synchronous or metachronous
liver metastases, which can be treated by surgery in
selected cases.2 Resection is the only treatment option
that improves long-term survival of patients with liver
metastases, but more than half of the resected patients
have a recurrence.3,4 Thus, there is an obvious need for
prognostic and predictive markers to determine the risk
of recurrence early after liver resection and to com-
mence more comprehensive follow-up and possibly
more aggressive adjuvant treatment for patients at high
1Transplantation and Liver Surgery Clinic, Helsinki University Hospital,
Helsinki, Finland
2Faculty of Medicine and Doctoral Programme in Clinical Research,
University of Helsinki, Helsinki, Finland
3Institute of Clinical Medicine, University of Helsinki, Helsinki, Finland
4Department of Clinical Chemistry, University of Helsinki and Helsinki
University Hospital, Helsinki, Finland
Corresponding author:
Reetta Peltonen, MD, Transplantation and Liver Surgery Clinic, Helsinki
University Hospital, Haartmaninkatu 4, P.O. Box 340, 00029 HUS, Finland.
Email: reetta.peltonen@hus.fi
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial
use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and
Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
risk. It would be valuable if measurement of serum or
plasma concentrations of tumour markers could be
used to predict the outcome of metastatic CRC after
curative resection.
At present, the best marker for CRC is carcinoem-
bryonic antigen (CEA), a glycoprotein belonging to the
immunoglobulin superfamily. However, about 20% of
CRC tumours have been reported not to produce ele-
vated serum levels of CEA in spite of metastatic dis-
ease.5 According to the European Group on Tumour
Markers (EGTM) and American Society of Clinical
Oncology (ASCO) guidelines, CEA is the only serum
marker that should be measured regularly in CRC
patients who are candidates for metastasectomy and
systemic therapy,6,7 but so far, there are no guidelines
for the use of tumour markers after curative resection
of CRC metastases.
Carbohydrate antigen 19-9 (CA19-9) has also been
used as a marker for CRC, but it is less sensitive than
CEA.8,9 It is not recommended in routine follow-up
after surgery,6,7 but it may have prognostic impact on
survival and in detection of recurrence, especially in
CEA-negative patients.10,11
Human chorionic gonadotropin (hCG) belongs to
the family of pituitary glycoprotein hormones compris-
ing luteinizing hormone, follicle-stimulating hormone
and thyroid-stimulating hormone. It has been sug-
gested to act as an angiogenic factor in tumour devel-
opment.12,13 Elevated serum concentrations of the free
b subunit of human chorionic gonadotropin (hCGb)
occur in several malignancies including digestive tract
cancers.14 In CRC, serum hCGb was shown to be an
independent prognostic factor, when measured before
surgery of the primary tumour.15,16
Tumour-associated trypsin-inhibitor (TATI) is a 6-
kDa peptide, which is produced by several tumours
and cell lines. It was initially found in the urine of a
patient with ovarian cancer,17 and later it was found to
be identical to pancreatic secretory trypsin-inhibitor
(PSTI), also called serine peptidase inhibitor Kazal-
type 1 (SPINK1), which is also produced in the pan-
creas.18 Increased serum concentrations of TATI occur
in several types of cancer, including ovarian, bladder,
kidney and pancreatic cancers.19 In primary CRC, high
preoperative concentrations of TATI in serum and high
expression of TATI in tumour tissue have been shown
to correlate with adverse prognosis and increased risk
of metachronous liver metastasis.20,21 However, TATI
expression in tumour tissue has been found to be asso-
ciated with better 5-year survival in metastatic CRC.22
Thus, the role of TATI as a prognostic marker remains
to be established.
The aim of this study was to evaluate whether ele-
vated preoperative or 3 months’ postoperative serum
or plasma concentrations of CEA, CA19-9, hCGb or
TATI were prognostic for recurrence or survival in
metastatic CRC after resection of liver metastases with
curative intent. Reliable prognostic markers would
help select patients who need more comprehensive




Serum and plasma samples were obtained from 168
CRC patients who underwent their first resection of
liver metastases at the tertiary liver surgery clinic of
Helsinki University Hospital between the years 1998
and 2007. The primary tumours (all adenocarcinoma)
had been operated between 1988 and 2007 at different
hospitals in Finland. Patients with extrahepatic metas-
tases were excluded. All patients alive had a minimum
follow-up time of 8 years after liver resection. After
resection, all patients were referred to consultation of a
medical oncologist for consideration of adjuvant treat-
ment and regular follow-up. All patients underwent
clinical examination, whole-body computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) and
blood tests at the resection unit at Helsinki University
Hospital 3months after liver resection.
The study was approved by the Ethics Committee of
the Helsinki University Hospital. Collection and analy-
sis of blood samples were approved by the National
Supervisory Authority for Welfare and Health
(Valvira). Clinical data were retrieved from patient
records. Information about dates and causes of death
were obtained from the Central Statistical Office of
Finland.
Plasma samples and assay procedures
Blood samples were drawn before liver resection and
3months after the operation in all resected patients;
3 month’s blood samples were taken at the postopera-
tive follow-up visit together with whole-body CT or
MRI and clinical examination. That time point was
considered optimal, since 3months after operation, the
postoperative complications have resolved, liver tissue
has regenerated and does not affect the tumour marker
levels anymore and possible adjuvant treatment has
been initiated. We also estimated that early tumour
marker rise most probably would be due to residual
disease and not recurrence.
The serum levels of CEA and CA19-9 were deter-
mined with an automatic analyser (Bayer, Tarrytown,
NY, USA). The upper reference limit for CEA was
5mg/L and that for CA19-9 was 26 kU/L based on the
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routinely used upper reference limits. The serum sam-
ples were analysed when taken, and the results were
retrieved from clinical records.
Plasma samples were stored at 280C until analysed
at the same time. The plasma concentrations of hCGb
were quantified by an immunofluorometric assay
(IFMA) based on monoclonal antibodies, and the
detection limit was 0.5 pmol/L.14 The plasma concen-
trations of TATI were determined by time-resolved
IFMA and the detection limit was 0.15mg/L.23
Statistics
Survival was calculated from the date of the first liver
resection. Endpoints were defined as follows: disease-
free survival (DFS): time to any recurrence of CRC or
death of any cause; and overall survival (OS): time to
death, irrespective of cause. Complete follow-up data
concerning OS were available from all patients. Data
cut-off date was 17 June 2015.
The tumour markers as non-normally distributed
were analysed with non-parametric tests, such as
Mann–Whitney U test. Correlations between s-CEA,
s-CA19-9, p-hCGb and p-TATI were calculated using
Spearman’s rho test and Cox regression model, and
those between the markers and clinical characteristics
using chi-square test. Cox regression was also used to
estimate the hazard ratio (HR) of s-CEA, s-CA19-9,
p-hCGb and p-TATI. Optimal cut-off values for hCGb
and TATI for 3-year survival were determined by recei-
ver operating characteristic (ROC) analysis. The impact
of tumour markers on DFS and OS was estimated
using Kaplan–Meier survival analysis and log rank sig-
nificance test as well as Cox regression model. In
Kaplan–Meier log rank analyses, patients with elevated
tumour marker values were compared to those with
marker values within reference limits. Univariate and
multivariate analyses were carried out using Cox regres-
sion model.
Statistical analyses were carried out and figures were
created using SPSS Statistics 22 (SPSS Inc., Chicago,




Liver resection was performed in 168 patients, of whom
101 (60%) were male and 101 (60%) had their primary
tumour in the colon (Table 1). The metastases were syn-
chronous in 89 (53%) and metachronous in 79 (47%)
cases. Median age of the patients at the time of liver
resection was 64.3 years (range: 36.3–81.5 years). At
that time, 48% of the patients were over 65 years old.
Disease-free and overall survival after liver resection
Median follow-up time for patients alive was 10.8 years
(range: 8.1–16.9 years) and 113 (67%) of all patients
died during follow-up. During the follow-up time, 115
(68.5%) of the patients had a recurrence, 24 (14%)
already within 3months after resection and 83 (49%)
within 3 years. The OS rate of all patients was 68.5%
(115/168) at 3 years and 50% (84/168) at 5 years after
resection. Median OS was 4.9 years (interquartile range
(IQR): 2.4–9.8 years; Table 1).
Markers in serum and plasma before and 3 months
after liver resection
The distributions of CEA, CA19-9, hCGb and TATI
measured before and 3months after liver resection are
shown in Table 2. The preoperative concentrations of
CEA correlated with CA19-9 (rho=0.395, p\ 0.001),
but not with the other markers; 3 months’ postopera-
tive CEA correlated with CA19-9 (rho=0.181,
p=0.019) and with TATI (rho=0.164, p=0.033),
but not with hCGb; 3 months’ CA19-9 correlated with
hCGb (rho=0.205, p=0.008), and TATI with hCGb
(rho=0.180, p=0.019).
We calculated the optimal cut-off values for CEA,
CA19-9, hCGb and TATI using ROC curve analyses
for prediction of 3-year survival after liver resection.
The ROC curves showed some difference in optimal
cut-off values for preoperative and postoperative sam-
ples. We decided to use the cut-off value of 5mg/L for
CEA (preoperative optimal cut-off value 4.35 and post-
operative 5.20mg/L based on ROC analyses) and
26kU/L for CA19-9 (preoperative optimal cut-off
value 80.5 and postoperative 11.5 kU/L based on ROC
analyses) according to the routinely used upper refer-
ence limits as the ROC analyses did not provide any
further improvement of accuracy. The cut-off values of
1.0 pmol/L for hCGb and 13mg/L for TATI were cho-
sen based on the 75th percentiles of both preoperative
and 3 months’ values.
Before surgery, the concentrations of CEA, CA19-9,
hCGb and TATI exceeded the cut-off limits in 56%,
36%, 24% and 48% of the cases, respectively, irrespec-
tive of possible neoadjuvant treatments; 3 months after
liver resection, the concentrations exceeded the limits in
16%, 14%, 23% and 46% of the cases, respectively.
Preoperative marker concentrations, DFS and OS
In Kaplan–Meier log rank analyses, elevated preopera-
tive concentrations of CEA (.5mg/L), CA19-9
(.26kU/L) or hCGb (.1.0 pmol/L) did not associate
with shorter DFS. Patients with elevated concentra-
tions of TATI (.13mg/L) had a shorter DFS within
3 years (p=0.017) and also within the whole follow-up
time (p=0.051).
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Elevated concentrations of CA19-9 (.26kU/L)
before liver resection associated with shorter OS
(p=0.006; Figure 1), as did also elevated CEA
(.5mg/L), but only within 3 years’ follow-up
(p=0.010). Preoperative concentrations of hCGb or
TATI did not associate with shorter OS.
In Cox regression analysis, the results were similar
(Table 3), also in multivariate analysis (data not shown).
Table 1. Characteristics and outcome of patients (N = 168) operated for colorectal liver metastases in 1998–2007.





At the operation of the primary tumour 62.9 (35.6–80.5)
At the first liver resection 64.3 (36.3–81.5)
<65 years at the first liver resection 88 (52%)
.65 years at the first liver resection 80 (48%)
Time from operation of primary tumour to liver resection 1.1 (0.1–6.7)
Primary tumour
Colon/rectosigmoid junction 101 (60%)
Rectum 67 (40%)
Dukes A 6 (3.6%)
Dukes B 34 (20.2%)
Dukes C 38 (22.6%)
Dukes D 84 (50.0%)
Dukes unknown 6 (3.6%)
Liver metastases
Synchronous (<6 months after the primary operation) 89 (53%)
Metachronous (.6 months after the primary operation) 79 (47%)
Number of liver metastases 1 (1–8)
Diameter of the largest liver metastasis 2.6 cm (0.1–10.0 cm)
Resection margins
R0 (resection margin histologically free) 157 (93.5%)
R1 (histologic neoplastic infiltration) 11 (6.5%)




Bevacizumab included 14 (8%)
Other/no treatment/unknown 86 (51%)




Bevacizumab included 14 (8%)
Other/no treatment/unknown 89 (53%)
Median follow-up time for patients alive 10.8 (8.1–16.9)
Median overall survival 4.9 (0.5–16.9)
Any recurrence after liver resection
Yes 115 (68.5%)
No 53 (31.5%)
Recurrence within 3 months after resection 24 (14.3%)
Recurrence after 3 months and within 3 years after resection 83 (49.4%)
Recurrence after 3 years 8 (4.8%)
Time to recurrence 11.3 months (1.2–73.0 months)
Disease-free survival
Alive, no recurrence 39 (23.2%)
Alive after/with recurrence 16 (9.5%)
Died of metastatic colorectal cancer 99 (58.9%)
Died of non-colorectal causesa 14 (8.3%)
Total number, percentage and median time in years (range) presented.
aOne patient had a recurrence, but died of another reason.
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Marker concentrations at 3 months after liver
resection, DFS and OS
In Kaplan–Meier log rank analyses, elevated concentra-
tions of CEA (.5mg/L) and CA19-9 (.26kU/L) at
3months after liver resection associated with shorter DFS
compared to patients, whose values were within reference
limits (p\ 0.001; Figure 2(a) and p=0.011; Figure 2(b),
respectively). Elevated concentrations of hCGb and TATI
at 3months did not associate with shorter DFS.
Elevated concentrations of CEA (.5mg/L), CA19-9
(.26kU/L) and hCGb (.1.0 pmol/L) at 3months
associated with shorter OS within 3 years after liver
resection (p\ 0.001, p=0.001 and p=0.017, respec-
tively), and CEA and CA19-9 also within the whole
follow-up time (p\ 0.001 and p=0.002, respectively;
Figure 3(a) and (b). TATI did not show correlation to
impaired OS.
The results of Cox regression analysis were in line
with these (Table 3), but in multivariate analysis only
Table 2. Concentrations of tumour markers before and after resection of colorectal liver metastases.
N = 168 CEA (mg/L) CA19-9 (kU/L) hCGb (pmol/L) TATI (mg/L)
Preoperative 3 months Preoperative 3 months Preoperative 3 months Preoperative 3 months
Median 7.2 2.4 15.5 7.0 0.6 0.6 12.7 12.7
Minimum \1.0 \1.0 \5.0 \5.0 0.0 0.0 0.0 4.1
Maximum 853.0 115.0 11310 33800 6.4 6.1 105.2 77.3
CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; hCGb: human chorionic gonadotropin b; TATI: tumour-associated trypsin-
inhibitor.
Figure 1. Preoperative values of CA19-9 in relation to overall
survival after liver resection.
Table 3. Results of Cox regression analysis in relation to 3-year DFS and OS.
3-year DFS p value OS p value
HR (CI) HR (CI)
Gender (female) 1.147 (0.781–1.687) 0.484 0.870 (0.595–1.274) 0.475
Age (.65 years) 1.181 (0.808–1.726) 0.389 1.201 (0.832–1.735) 0.328
Primary tumour in colon 0.753 (0.514–1.103) 0.145 0.770 (0.531–1.114) 0.166
T3-4 1.178 (0.752–1.845) 0.474 1.010 (0.662–1.541) 0.964
N 1 1.393 (0.881–2.204) 0.157 1.142 (0.738–1.767) 0.551
Synchronous liver metastases 1.485 (1.011–2.181) 0.044 0.995 (0.688–1.437) 0.978
Biggest liver metastasis <2.0 cm 1.056 (0.714–1.563) 0.785 0.959 (0.655–1.403) 0.829
Biggest liver metastasis .2.0 cm 0.947 (0.640–1.401) 0.785 1.043 (0.713–1.526) 0.829
R1 resection 0.784 (0.344–1.787) 0.563 1.068 (0.520–2.192) 0.858
Neoadjuvant chemotherapy 1.322 (0.904–1.933) 0.150 0.875 (0.605–1.264) 0.476
Adjuvant chemotherapy 0.893 (0.610–1.307) 0.561 0.558 (0.383–0.811) 0.002
CEA .5.0 mg/L preoperative 1.042 (0.710–1.528) 0.834 1.299 (0.895–1.885) 0.168
CEA .5.0 mg/L at 3 months 3.861 (2.427–6.143) \0.001 3.684 (2.345–5.785) \0.001
CA19-9 .26 kU/L preoperative 1.241 (0.840–1.833) 0.278 1.692 (1.164–2.459) 0.006
CA19-9 .26 kU/L at 3 months 1.523 (0.906–2.558) 0.112 2.113 (1.313–3.401) 0.002
hCGb .1.0 pmol/L preoperative 0.969 (0.615–1.526) 0.891 1.179 (0.773–1.798) 0.444
hCGb .1.0 pmol/L at 3 months 1.154 (0.732–1.819) 0.536 1.475 (0.967–2.249) 0.071
TATI .13.0 mg/L preoperative 1.584 (1.082–2.318) 0.018 1.214 (0.840–1.754) 0.302
TATI .13.0 mg/L at 3 months 1.155 (0.791–1.688) 0.456 1.108 (0.767–1.600) 0.586
HR: hazard ratio; CI: confidence interval; DFS: disease-free survival; OS: overall survival; CEA: carcinoembryonic antigen; CA19-9: carbohydrate
antigen; hCGb: human chorionic gonadotropin b; TATI: tumour-associated trypsin-inhibitor. Statistically significant p values are marked in bold.
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elevated CEA remained statistically significant (data
not shown).
Elevated marker concentrations at 3 months
and recurrence
At the 3 months’ control, 24 patients (14.3%) had already
a recurrence. When we excluded them from the analyses,
there were altogether 144 patients, of whom 91 (54.2%)
developed recurrence after 3months as follows: 85% of
the patients with elevated CEA (total N=13), 80% with
elevated CA19-9 (total N=15), 54% with elevated
hCGb (total N=28), and 63% of those with elevated
TATI (total N=65). Altogether 131 patients had a nor-
mal CEA level, and of those, 80 (61%) had a recurrence
later. In Kaplan–Meier log rank analysis, these patients
developed recurrence later than those with elevated CEA
(p=0.001). Of the patients who had a normal CEA level
but developed recurrence, 9 had elevated CA19-9, 12 ele-
vated hCGb, and 33 elevated TATI at 3months.
Figure 2. The 3 months’ values of (a) CEA and 3-year disease-free survival and (b) CA19-9 and long-term disease-free survival.
Figure 3. The 3 months’ values of (a) CEA and (b) CA19-9 in relation to overall survival after liver resection.
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Univariate and multivariate analyses
In Cox regression analysis, possible neoadjuvant or
adjuvant chemotherapy before or after liver resection
did not show statistical correlation to DFS, but
adjuvant treatment was associated with better OS
(p=0.002; Table 3). Synchronous liver metastases
were associated with shorter 3-year DFS compared to
metachronous liver metastases (p=0.044; Table 3).
The other results of univariate analyses are shown in
Table 3.
Multivariate analyses were carried out with adjust-
ment for synchronous liver metastases or adjuvant che-
motherapy (data not shown). In these analyses,
elevated CEA (.5.0mg/L) at 3months correlated with
impaired 3-year DFS and OS (p\ 0.001, HR 3.776 and
p\ 0.001, HR 3.715). Adjuvant treatment remained
statistically significant in relation to OS (p=0.001, HR
0.522). Preoperatively or 3months postoperatively ele-
vated CA19-9 (.26kU/L) did not show statistically sig-
nificant correlations, nor preoperatively elevated TATI
(data not shown).
Discussion
To our knowledge, this is the first study to examine the
prognostic value of CEA, CA19-9, TATI, and hCGb
3months after liver resection of CRC metastases. Our
results show that elevated CEA, CA19-9 and hCGb
marker concentrations 3months after curative-intent
liver resection have prognostic value. Preoperatively
elevated CEA and CA19-9 were associated with shorter
survival.
The strengths of this retrospective study are a quite
large patient material, a long and comprehensive
follow-up time, and all consecutive, eligible patients at
a single institution included. The limitations of our
study are the heterogeneity of the patient material,
missing information on the BRAF mutation status,
and the lack of standardised postoperative measure-
ment point for tumour markers.
To minimise heterogeneity, we only included patients
with liver-only metastases, patients with extrahepatic
metastases were excluded based on aberrant tumour
marker behaviour, and only the first liver resection was
taken into consideration. Missing BRAF information is
a limitation of this study as it may partly explain the
fact that 24 (14.3%) patients had a recurrence already
at 3months after resection. BRAF mutation status was
not routinely assessed in 1998–2007, and thus, one sig-
nificant prognostic factor is missing. In any case, it is
likely that recurrences less than 3months after liver
resection are due to residual disease and not due to
recurrence.
Very little data about postoperative marker measure-
ment is available and even less on the timing of
assessment. Too short an interval postoperatively is
affected by postoperative complications like bile duct
interference with CA19-9 levels, effects of postoperative
growth factors on tumour marker levels, inter-
individual variation in postoperative tumour marker
half-life, and the timing of adjuvant treatment initia-
tion. Thus, 3months was considered an optimal time
point for predictive tumour marker assessment after
liver resection.
Preoperatively elevated CEA and CA19-9 were asso-
ciated with shorter survival, as shown in previous stud-
ies,24,25 also after neoadjuvant chemotherapy in recent
studies.26–28
Increased levels of CEA 3months after liver resec-
tion showed the strongest association with early recur-
rence and impaired OS after liver resection, which is in
line with the results of a recent Japanese study.29 They
measured CEA levels before resection of colorectal liver
metastases and within 1month after it and showed that
elevated postoperative CEA (.5mg/L) was a significant
risk factor for early recurrence. Elevation of CEA has
also been shown to be of value in follow-up after liver
resection.30 In our study, however, 78% of patients (90/
115) who experienced a recurrence did not have ele-
vated CEA concentrations at 3months. That makes it
obvious that if we only look at the CEA levels, a nota-
ble number of patients with a high risk of recurrence
will go undetected. It is still worth noticing that the
patients with a normal CEA level at 3months devel-
oped recurrence later than those with elevated CEA,
and it is possible that their marker level had not yet
risen at our measurement point.
Elevated concentrations of CA19-9 3months after
liver resection correlated not only with impaired OS,
but also with shorter DFS in longer follow-up. This is
in line with the recent Japanese study evaluating the ris-
ing of CA19-9 within a month from liver resection.29 In
metastatic CRC, elevated CA19-9 levels have been
associated with poor survival,10,11,31 which corresponds
to our results. Interestingly, there were nine patients
with elevated CA19-9, but normal CEA levels 3months
after liver resection, who developed a recurrence. Thus,
measuring CA19-9 is useful at least for CEA-negative
patients. This is in line with the findings in an intensive
follow-up programme after liver resection, in which ele-
vations of CEA and CA19-9 were complimentary, but
association between tumour markers and prognosis
was not presented.32 It is worth noticing, however, that
normal levels of CEA and CA19-9 at 3months after
liver resection do not exclude later recurrence.
The results for hCGb are interesting. Elevated levels
(.1 pmol/L) 3months after liver resection showed a
statistically significant correlation with both impaired
DFS and OS. Thus, hCGb is a marker of adverse prog-
nosis for selected patients as previously shown in preo-
perative samples,33 but further research is needed
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before its use may be recommended in follow-up after
liver resection for metastases of CRC.
Previous results on the use of TATI in CRC have
been conflicting. High serum levels and tissue expres-
sion in the primary tumour have been shown to corre-
late with the risk of metastases.20,21 Nevertheless, in
metastatic CRC, high TATI expression in the primary
tumour tissue has been associated with better 5-year
survival.15,22 However, in our study, TATI was not
associated with impaired survival, and results for recur-
rence were conflicting. TATI does not seem to be of
prognostic or predictive value after liver resection for
metastases of CRC. As TATI may also behave as an
acute-phase protein,26 it is possible that elevated con-
centrations at 3months are caused by ongoing tissue
repair and that TATI may be more informative at later
stages.
Measuring tumour markers before liver resection
gives important information on OS and the risk of
recurrence, which should be taken into account when
considering liver resection. Preoperatively high values
of CEA and CA19-9 do not correlate directly with high
risk of early recurrence, but they are a sign of adverse
outcome. Postoperatively elevated values, however,
show a clear risk of recurrence. In this patient group, it
might be worth considering longer or more intensive
adjuvant treatment after resection and more frequent
follow-up to find resectable recurrences.
Conclusion
CEA remains the best prognostic and predictive mar-
ker for CRC with liver metastases. Elevated serum con-
centrations of CEA at baseline and 3months after
resection of liver metastases are a sign of adverse prog-
nosis. In patients with normal CEA concentrations,
assay of CA19-9 and possibly hCGb are of additional
value. The levels of these markers appear informative
for prediction of recurrence, but cannot yet be used as
evidence to change the strategies for follow-up or treat-
ment. Measuring tumour markers 3months after liver
resection gives additional information with CEA and
CA19-9.
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Ulf-Håkan Stenman’s laboratory. Helena Isoniemi designed
and directed the study, participated in the statistical analyses
and interpreted results. All authors contributed to writing the
manuscript. All authors have read and approved the final
manuscript.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of this
article.
Funding
The author(s) received no financial support for the research,
authorship, and/or publication of this article.
References
1. Torre LA, Bray F, Siegel RL, et al. Global cancer statis-
tics, 2012. CA Cancer J Clin 2015; 65: 87–108.
2. Misiakos EP, Karidis NP and Kouraklis G. Current
treatment for colorectal liver metastases. World J Gastro-
enterol 2011; 17: 4067–4075.
3. Adam R, de Gramont A, Figueras J, et al. Managing
synchronous liver metastases from colorectal cancer: a
multidisciplinary international consensus. Cancer Treat
Rev 2015; 41: 729–741.
4. Van Cutsem E, Cervantes A, Adam R, et al. ESMO con-
sensus guidelines for the management of patients with
metastatic colorectal cancer. Ann Oncol 2016; 27:
1386–1422.
5. Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA
levels for detecting recurrent colorectal cancer. Cochrane
Database Syst Rev 2015; 12: CD011134.
6. Duffy MJ, van Dalen A, Haglund C, et al. Tumour mar-
kers in colorectal cancer: European Group on Tumour
Markers (EGTM) guidelines for clinical use. Eur J Can-
cer 2007; 43: 1348–1360.
7. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update
of recommendations for the use of tumor markers in gas-
trointestinal cancer. J Clin Oncol 2006; 24: 5313–5327.
8. Bagaria B, Sood S, Sharma R, et al. Comparative study
of CEA and CA19-9 in esophageal, gastric and colon
cancers individually and in combination (ROC curve
analysis). Cancer Biol Med 2013; 10: 148–157.
9. Okamura R, Hasegawa S, Hida K, et al. The role of peri-
odic serum CA19-9 test in surveillance after colorectal
cancer surgery. Int J Clin Oncol 2017; 22: 96–101.
10. Kouri M, Pyrhonen S and Kuusela P. Elevated CA19-9
as the most significant prognostic factor in advanced col-
orectal carcinoma. J Surg Oncol 1992; 49: 78–85.
11. Giessen-Jung C, Nagel D, Glas M, et al. Preoperative
serum markers for individual patient prognosis in stage
I-III colon cancer. Tumour Biol 2015; 36: 7897–7906.
12. Zygmunt M, Herr F, Keller-Schoenwetter S, et al. Char-
acterization of human chorionic gonadotropin as a novel
angiogenic factor. J Clin Endocrinol Metab 2002; 87:
5290–5296.
8 Tumor Biology
13. Iles RK, Delves PJ and Butler SA. Does hCG or hCGb
play a role in cancer cell biology? Mol Cell Endocrinol
2010; 329: 62–70.
14. Stenman UH, Alfthan H and Hotakainen K. Human
chorionic gonadotropin in cancer. Clin Biochem 2004; 37:
549–561.
15. Lundin M, Nordling S, Carpelan-Holmstrom M, et al. A
comparison of serum and tissue hCG beta as prognostic
markers in colorectal cancer. Anticancer Res 2000; 20:
4949–4951.
16. Louhimo J, Finne P, Alfthan H, et al. Combination of
HCGbeta, CA 19-9 and CEA with logistic regression
improves accuracy in gastrointestinal malignancies.
Anticancer Res 2002; 22: 1759–1764.
17. Stenman UH, Huhtala ML, Koistinen R, et al. Immuno-
chemical demonstration of an ovarian cancer-associated
urinary peptide. Int J Cancer 1982; 30: 53–57.
18. Huhtala ML, Pesonen K, Kalkkinen N, et al. Purification
and characterization of a tumor-associated trypsin inhibi-
tor from the urine of a patient with ovarian cancer. J Biol
Chem 1982; 257: 13713–13716.
19. Itkonen O and Stenman UH. TATI as a biomarker. Clin
Chim Acta 2014; 431: 260–269.
20. Gaber A, Johansson M, Stenman UH, et al. High expres-
sion of tumour-associated trypsin inhibitor correlates
with liver metastasis and poor prognosis in colorectal
cancer. Br J Cancer 2009; 100: 1540–1548.
21. Gaber A, Nodin B, Hotakainen K, et al. Increased serum
levels of tumour-associated trypsin inhibitor indepen-
dently predict a poor prognosis in colorectal cancer
patients. BMC Cancer 2010; 10: 498.
22. Koskensalo S, Hagstrom J, Louhimo J, et al. Tumour-
associated trypsin inhibitor TATI is a prognostic marker
in colorectal cancer. Oncology 2012; 82: 234–241.
23. Janeiro E, Guimaraes J, Stenman UH, et al. Validation
and comparison of tumor-associated trypsin inhibitor
(TATI) immunoassays. Clin Chim Acta 2012; 413:
1244–1248.
24. Ryuk JP, Choi GS, Park JS, et al. Predictive factors and
the prognosis of recurrence of colorectal cancer within
2 years after curative resection. Ann Surg Treat Res 2014;
86: 143–151.
25. Bredt LC and Rachid AF. Predictors of recurrence after
a first hepatectomy for colorectal cancer liver metas-
tases: a retrospective analysis. World J Surg Oncol 2014;
12: 391.
26. Neofytou K, Giakoustidis A, Neves MC, et al. Increased
carcinoembryonic antigen (CEA) following neoadjuvant
chemotherapy predicts poor prognosis in patients that
undergo hepatectomy for liver-only colorectal metastases.
Langenbecks Arch Surg 2017; 402: 599–605.
27. Sakamoto Y, Miyamoto Y, Beppu T, et al. Post-che-
motherapeutic CEA and CA19-9 are prognostic factors
in patients with colorectal liver metastases treated with
hepatic resection after oxaliplatin-based chemotherapy.
Anticancer Res 2015; 35: 2359–2368.
28. De Haas RJ, Wicherts DA, Flores E, et al. Tumor mar-
ker evolution: comparison with imaging for assessment of
response to chemotherapy in patients with colorectal liver
metastases. Ann Surg Oncol 2010; 17: 1010–1023.
29. Takamoto T, Sugawara Y, Hashimoto T, et al. Dynamic
assessment of carcinoembryonic antigen in the first
month after liver resection for colorectal liver metastases
as a rapid-recurrence predictor. J Surg Oncol 2016; 113:
463–468.
30. Hara M, Sato M, Takahashi H, et al. Carcinoembryonic
antigen elevation in post-hepatectomy patients with col-
orectal cancer liver metastasis indicates recurrence with
high accuracy. Hepatogastroenterology 2013; 60:
1935–1939.
31. Kouri M, Nordling S, Kuusela P, et al. Poor prognosis
associated with elevated serum CA 19-9 level in advanced
colorectal carcinoma, independent of DNA ploidy or
SPF. Eur J Cancer 1993; 29A: 1691–1696.
32. Bhattacharjya S, Aggarwal R and Davidson BR. Inten-
sive follow-up after liver resection for colorectal liver
metastases: Results of combined serial tumour marker
estimations and computed tomography of the chest and
abdomen – a prospective study. Br J Cancer 2006; 95:
21–26.
33. Louhimo J, Carpelan-Holmstrom M, Alfthan H, et al.
Serum HCG beta, CA 72-4 and CEA are independent
prognostic factors in colorectal cancer. Int J Cancer
2002; 101: 545–548.
Peltonen et al. 9
